阿仑单抗作为那他珠单抗停药后多发性硬化症复发的挽救性治疗：临床病例及文献复习。
Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review.
机构信息
Multiple Sclerosis Centre, ULSS8 Berica, Ospedale San Bortolo, Contrà San Bortolo 16, 36100 Vicenza, Italy.
Multiple Sclerosis Centre, Department of Neurosciences DNS, Università degli Studi di Padova, via Giustiniani 2, 35128 Padova, Italy.
出版信息
Mult Scler Relat Disord. 2019 May;30:262-264. doi: 10.1016/j.msard.2019.03.002. Epub 2019 Mar 5.
INTRODUCTION
Natalizumab break exposes multiple sclerosis (MS) patients to a high risk of disease reactivation or rebound, whose prevention and treatment constitute a clinical challenge.
CASE PRESENTATION
We describe a dramatic case of MS rebound, characterized by the development of severe neurological and psychiatric symptoms, following natalizumab break. Alemtuzumab rapidly and completely suppressed brain inflammation as demonstrated by clinical and radiological findings.
CONCLUSIONS
Our case further adds to the available literature evidence on Alemtuzumab as first-choice rescue therapy following Natalizumab discontinuation.
简介
那他珠单抗停药会使多发性硬化症（MS）患者面临疾病复发或反弹的高风险，其预防和治疗构成临床挑战。
病例介绍
我们描述了一例 MS 反弹的戏剧性病例，其特征是在那他珠单抗停药后出现严重的神经和精神症状。阿仑单抗迅速且完全抑制了脑内炎症，这一点从临床和影像学发现中得到证实。
结论
我们的病例进一步增加了阿仑单抗作为那他珠单抗停药后的首选挽救治疗的现有文献证据。
Zotero 插件